Investigating the effects of a heart medication on hypertensive patients with different body weights
Official title: Effect of Sacubitril/Valsartan on Cardiac Function Assessed by Cardiac Magnetic Resonance (CMR) in Hypertensive Patients Stratified by Body Mass Index (BMI): A Real World Study
Run by Beijing Friendship Hospital · NCT05498675 · Data updated 2026-11-12
This study is testing how a heart medication called sacubitril/valsartan affects heart function in people with high blood pressure who have different body weights.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Beijing Friendship Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | September 1, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | February 13, 2025 |
| Trial ID | NCT05498675 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18-70 with essential hypertension and no major barriers to providing consent.
✕Probably not a fit
Patients with secondary hypertension, recent cardiovascular events, or severe concomitant diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate how sacubitril/valsartan affects cardiac function in hypertensive patients, particularly focusing on differences based on body mass index (BMI). By utilizing cardiac magnetic resonance (CMR) imaging, the study will compare the cardiac structure and function of patients taking sacubitril/valsartan against those on other antihypertensive medications. The research seeks to clarify the potential benefits of this medication for various BMI groups in a real-world setting.
Why it matters
Potential benefit: If successful, this study could provide insights into personalized treatment strategies for hypertensive patients based on their BMI, potentially improving cardiac health outcomes.
How similar studies have gone: While there is existing research on sacubitril/valsartan, this specific focus on BMI stratification in hypertensive patients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with essential hypertension * 18-70 years old * No major barriers to provide written consent Exclusion Criteria: * Secondary hypertension, except because of sleep apnea * cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months * Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases) * Unable to understand or comply with the study procedures
Where it's running
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Rongchong Huang, M.D. — Beijing Friendship Hospital
- Study coordinator: Rongchong Huang, M.D.
- Email: rchuang@ccmu.edu.cn
- Phone: +86-13811039417
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clazakizumab for adults with high hsCRP at risk for a heart event
This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.
-
Structured management of adult cardiovascular risk factors in outpatient care
This project will try a structured clinic approach to managing blood pressure, cholesterol, diabetes, and weight in adults with cardiovascular risk factors to see if it improves risk control and outcomes.
-
Digital tool for doctors to prescribe exercise for people with cardiovascular risk factors
This project will test whether a new digital tool helps doctors create personalized exercise plans for adults with cardiovascular risk factors.
-
Postpartum program to prevent cardiometabolic problems after preeclampsia
This study will test a 9-month app-based support program to lower blood pressure and help with weight loss in first-time mothers who recently had preeclampsia.
-
Sisters of Heart: community health worker support to improve heart health in migrant farmworker women
This trial tests whether peer support and help accessing community resources from community health workers can reduce stress and improve heart health measures in Spanish- or English-speaking migrant farmworker women aged 18–45.
-
Oral SPM-enriched marine oil to reduce inflammation-driven vascular ageing in obese people with high blood pressure
This trial tests whether taking an oral SPM-enriched marine oil supplement (LIPINOVA) can reduce blood-vessel inflammation and signs of vascular ageing in adults with obesity and controlled hypertension.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.